These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Intraocular pressure lowering effect of brinzolamide 1.0% as adjunctive therapy to latanoprost 0.005% in patients with open angle glaucoma or ocular hypertension: an uncontrolled, open-label study. Shoji N; Ogata H; Suyama H; Ishikawa H; Suzuki H; Morita T; Kawai H; Nishimoto H; Nemoto T; Shimizu K Curr Med Res Opin; 2005 Apr; 21(4):503-8. PubMed ID: 15899098 [TBL] [Abstract][Full Text] [Related]
26. Development of brimonidine niosomes laden contact lenses for extended release and promising delivery system in glaucoma treatment. Tripathi S; Yadav KS Daru; 2024 Jun; 32(1):161-175. PubMed ID: 38158475 [TBL] [Abstract][Full Text] [Related]
27. Latanoprost niosomes as a sustained release ocular delivery system for the management of glaucoma. Fathalla D; Fouad EA; Soliman GM Drug Dev Ind Pharm; 2020 May; 46(5):806-813. PubMed ID: 32281424 [No Abstract] [Full Text] [Related]
28. [Pharmacological profiles of latanoprost (Xalatan), a novel anti-glaucoma drug]. Nomura S; Hashimoto M Nihon Yakurigaku Zasshi; 2000 May; 115(5):280-6. PubMed ID: 10872179 [TBL] [Abstract][Full Text] [Related]
29. An evaluation of the fixed-combination of latanoprost and timolol for use in open-angle glaucoma and ocular hypertension. Feldman RM Expert Opin Pharmacother; 2004 Apr; 5(4):909-21. PubMed ID: 15102573 [TBL] [Abstract][Full Text] [Related]
30. Reduction of intraocular pressure with treatment of latanoprost once daily in patients with normal-pressure glaucoma. Rulo AH; Greve EL; Geijssen HC; Hoyng PF Ophthalmology; 1996 Aug; 103(8):1276-82. PubMed ID: 8764799 [TBL] [Abstract][Full Text] [Related]
31. Selectively coated contact lenses by nanoelectrospray (nES) to fabricate drug-eluting contact lenses for treating ocular diseases. Tam CH; Alexander MS; Sanderson J; Qi S Med Eng Phys; 2024 Feb; 124():104110. PubMed ID: 38418021 [TBL] [Abstract][Full Text] [Related]
32. Long-term effect of latanoprost/timolol fixed combination in patients with glaucoma or ocular hypertension: a prospective, observational, noninterventional study. Schwenn O; Heckmann B; Guzy C; Miller PJ BMC Ophthalmol; 2010 Sep; 10():21. PubMed ID: 20825668 [TBL] [Abstract][Full Text] [Related]
33. Biodegradable nanoparticles for controlled subconjunctival delivery of latanoprost acid: in vitro and in vivo evaluation. Preliminary results. Giarmoukakis A; Labiris G; Sideroudi H; Tsimali Z; Koutsospyrou N; Avgoustakis K; Kozobolis V Exp Eye Res; 2013 Jul; 112():29-36. PubMed ID: 23603320 [TBL] [Abstract][Full Text] [Related]
34. The additive intraocular pressure-lowering effect of latanoprost in combined therapy with other ocular hypotensive agents. Hoyng PF; Rulo A; Greve E; Watson P; Alm A Surv Ophthalmol; 1997 Feb; 41 Suppl 2():S93-8. PubMed ID: 9154283 [TBL] [Abstract][Full Text] [Related]
35. Reduction of IOP with latanoprost. Hoste AM Ophthalmology; 1997 Jun; 104(6):895-7. PubMed ID: 9186420 [No Abstract] [Full Text] [Related]
37. Use of latanoprost in the treatment of glaucoma associated with Sturge-Weber syndrome. Yang CB; Freedman SF; Myers JS; Buckley EG; Herndon LW; Allingham RR Am J Ophthalmol; 1998 Oct; 126(4):600-2. PubMed ID: 9780111 [TBL] [Abstract][Full Text] [Related]